Harashima SI, et al. - This trial incorporated a scrutiny of the efficacy and safety of the sodium glucose co-transporter 2 (SGLT2) inhibitor canagliflozin as an add-on therapy in Japanese subjects with type 2 diabetes mellitus (T2DM) and inadequate glycaemic control with a glucagon-like peptide-1 receptor agonists (GLP-1RAs) (≥12 weeks). Researchers observed that the incidence of adverse events (AEs), adverse drug reactions, and hypoglycaemia were 71.8%, 32.4%, and 9.9%, respectively. Mild hypoglycaemic events were reported in all cases. Hence, it was exhibited that the long-term combination of canagliflozin with a GLP-1RA was effective and well tolerated in the study cohort.